Document Detail

Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group.
MedLine Citation:
PMID:  15454253     Owner:  NLM     Status:  MEDLINE    
The study sought to evaluate the response to cyclophosphamide (CPM) in hepatoblastoma (HB). Patients with a refractory or relapsing HB after first-line therapy as per SIOPEL 2 and 3 protocols were eligible. All patients were to receive two courses of CPM 2 g/m(2) on days 1 and 2 at 3-week intervals. Eighteen patients were included; 17 were evaluable for response. Prior treatment was cisplatinum alone (1 patient) or cisplatinum-carboplatin-doxorubicin (17 patients). The disease status at the beginning of CPM was: progressive during first-line treatment (10 patients), persistent unresectable disease at the end of the protocol (2 patients), relapse (6 patients). Tumour response was partial response (1 patient), stable disease (1 patient), progressive disease (15 patients) and not evaluable in one. All patients died, 17 of progressive disease and one of surgery complications. The low response rate (1/17) led the SIOPEL group to conclude that single-agent CPM is not effective for the treatment of relapsing or refractory HB.
Walter Daniel Cacciavillano; Laurence Brugières; Margaret Childs; Elisabeth Shafford; Penelope Brock; Jon Pritchard; Rudolf Mailbach; Marcello Scopinaro; Giorgio Perilongo
Related Documents :
20830473 - Histopathology of aseptic necrosis of the femoral head in sickle cell disease.
8586873 - Haematological aspect of malaria in a population based hospital, saudi arabia.
2296253 - Dexamethasone suppression test in patients with parkinson's disease.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  40     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-29     Completed Date:  2004-11-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  2274-9     Citation Subset:  IM    
Department of Paediatric Oncology, Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Alkylating / administration & dosage*,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Child, Preschool
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage*,  adverse effects
Doxorubicin / administration & dosage
Hepatoblastoma / drug therapy*
Liver Neoplasms / drug therapy*
Middle Aged
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 41575-94-4/Carboplatin; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal car...
Next Document:  Symptom interval in young people with bone cancer.